Accuray Appoints Steve La Neve as CEO to Boost Operational Performance and Competitiveness

Accuray's Leadership Shift Paves the Way for Enhanced Operational Performance

Accuray Incorporated embarks on a significant organizational transformation, marked by the appointment of Steve La Neve as the new Chief Executive Officer on October 20, 2025. La Neve takes over from Suzanne Winter, who retires after six years of service but will remain involved through the end of November to facilitate a smooth transition. This leadership change is part of a broader strategy initiated by the Board of Directors to bolster operational performance and increase competitiveness in the medical technology sector. With La Neve at the helm, Accuray aims to implement initiatives throughout the current fiscal year that are focused on improving operating margins and enhancing organizational agility.

Steve La Neve brings a wealth of experience to his new role, with over 40 years in the international medical technology landscape. His previous leadership positions at esteemed companies such as Globus Medical Inc., Bone Biologics Corporation, and Medtronic equip him with the insights necessary to navigate the complexities of the industry. In his inaugural remarks, La Neve expresses enthusiasm for Accuray’s mission to deliver impactful radiation therapy solutions. He notes the company’s substantial installed base and strong order backlog, key indicators that position Accuray favorably in the rapidly expanding markets.

In addition to La Neve's appointment, Accuray strengthens its leadership team with the nomination of Chan W. Galbato to the Board of Directors and the designation of Steven F. Mayer as Transformation Board Sponsor. These strategic appointments reflect Accuray’s commitment to driving execution and fostering a customer-focused organization. Chairman of the Board, Joe Whitters, underscores the critical nature of these changes in advancing the company’s growth strategy, emphasizing the need for strong leadership to navigate the evolving landscape of medical technology.

Accuray's recent leadership changes signal a proactive approach to enhancing its market presence. By focusing on operational efficiency and customer-centric initiatives, the company positions itself to capitalize on growth opportunities within the medical technology sector. The upcoming fiscal year will be pivotal as La Neve and his team implement strategies aimed at fortifying Accuray’s innovative reputation and ensuring the delivery of cutting-edge radiation therapy solutions.

As Accuray transitions under new leadership, the company remains committed to its core mission and the development of innovative medical technologies. The Board's strategic initiatives are designed not just to improve performance metrics but to solidify Accuray's role as a leader in providing impactful healthcare solutions, thereby ensuring its relevance in an increasingly competitive market.